Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
Type:
Grant
Filed:
February 11, 2008
Date of Patent:
February 19, 2013
Assignee:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: A method for administering nerve growth factor to treat cravings is provided. Pharmaceutical compositions for the treatment of cravings comprising nerve growth factor are also provided.
Abstract: The present invention provides methods for stimulating neuronal survival, growth and regeneration by administering SLPIs to animals, such as humans. These methods can be used to treat a variety of neurological conditions such as neural injuries and degenerative diseases in subjects in need thereof.
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
February 5, 2013
Assignee:
Research Foundation of City University of New York
Abstract: Methods and compositions for diagnosis and treatment of neurodegenerative disorders are disclosed. The methods and compositions apply the discovery of the correlation between an hGDH2 gene polymorphism and the occurrence of atypical Parkinson's Disease.
Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.
Type:
Grant
Filed:
October 11, 1999
Date of Patent:
November 27, 2012
Assignee:
Scil Proteins GmbH
Inventors:
Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.
Type:
Grant
Filed:
September 17, 2010
Date of Patent:
October 30, 2012
Assignee:
The University of Queensland
Inventors:
Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
Abstract: A method of neuroprotection which comprises administration of an AMPK inhibitor to a patient who is experiencing or has experienced a stroke, the compound being an AMPK inhibitor. Treatments with these agents significantly reduce the size of infarcts, and therefore minimize the loss of brain tissue and neurons. Thus, function can be preserved after stroke or ischemic injury in the brain. Similarly, neuronal loss can be minimized in degenerative diseases that cause neuronal compromise by perturbing energy utilization and availability in neurons.
Type:
Grant
Filed:
March 23, 2005
Date of Patent:
October 23, 2012
Assignees:
FASgen, LLC, Johns Hopkins University
Inventors:
Louise D. McCullough, Jill Sturdivant, Gabriele V. Ronnett
Abstract: The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of spinal muscular atrophy (SMA), in which said compounds up-regulate the post-transcriptional expression of SMN1 or SMN2.
Type:
Grant
Filed:
June 23, 2008
Date of Patent:
October 9, 2012
Assignee:
PTC Therapeutics, Inc.
Inventors:
Anuradha Bhattacharyya, Bansri S. Furia, Meenal Patel, Sergey V. Paushkin, Love Volkova
Abstract: The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of muscular dystrophy (MD), or a form thereof, in which said compounds increase the post-transcriptional expression of a target gene (i.e., mIGF1, ITGA7, or UTRN).
Type:
Grant
Filed:
June 20, 2008
Date of Patent:
October 9, 2012
Assignee:
PTC Therapeutics, Inc.
Inventors:
Westley J Friesen, Nikolai Naryshkin, Meenal Patel, Charles Romfo, Ellen Welch, Yuki Tomizawa, Jin Zhuo
Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
Type:
Grant
Filed:
March 28, 2006
Date of Patent:
September 25, 2012
Assignee:
Aventis Pharma S.A.
Inventors:
Han Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
Abstract: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.
Abstract: A chaperone protein Q2 and ?-amyloid can form a complex. This complex can be detected in a biological sample, such as, for example, tissues or fluids from a mammal. Q2 levels can also be detected in a biological sample. A method for determining the Q2 level in a biological sample and comparing that level to a normal Q2 level can be used to detect, screen, diagnose, or otherwise determine a person's susceptibility to Alzheimer's disease such as, for example, the presence or absence of Alzheimer's disease, of symptoms of this disease, of factors leading to or associated with this disease, of likelihood of developing this disease, and the like. In one embodiment, a decline in Q2 level correlates to an increased likelihood of developing Alzheimer's disease. In another embodiment, a decline in Q2 level correlates to an increase in ?-amyloid aggregation. The method may further include screening for an apolipoprotein E genotype, which is associated with Alzheimer's disease.
Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
Type:
Grant
Filed:
April 1, 2009
Date of Patent:
June 26, 2012
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
Abstract: The present invention features polypeptides having activity of human neurogenin3 (hNgn3), and nucleic acid encoding such polypeptide. The invention also features use of islet transcription factors such as hNgn3 to facilitate production of pancreatic islet cells from progenitor cells, and to facilitate insulin delivery by production of islet cells so produced.
Type:
Grant
Filed:
August 14, 2003
Date of Patent:
June 5, 2012
Assignee:
The Regents of the University of California
Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.
Type:
Grant
Filed:
March 1, 2009
Date of Patent:
May 1, 2012
Assignee:
University of Utah Research Foundation
Inventors:
Margot Mayer-Proschel, Mahendra S. Rao, Patrick A. Tresco, Darin J. Messina
Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.
Type:
Grant
Filed:
September 26, 2005
Date of Patent:
April 17, 2012
Assignee:
Syntaxin Limited
Inventors:
Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
Abstract: The present invention relates to the discovery of a composition including a seven-amino acid peptide that promotes neuronal survival, inhibits inflammation, and is a potent inhibitor of sPL2A, and uses thereof.
Type:
Grant
Filed:
October 12, 2007
Date of Patent:
January 31, 2012
Assignee:
Philadelphia Health & Education Corporation
Inventors:
Timothy J. Cunningham, Lihua Yao, Jeffrey I. Greenstein
Abstract: The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases.